In the past week, DYN stock has gone down by -12.13%, with a monthly decline of -10.18% and a quarterly plunge of -34.07%. The volatility ratio for the week is 8.63%, and the volatility levels for the last 30 days are 6.65% for Dyne Therapeutics Inc The simple moving average for the last 20 days is 1.00% for DYN stock, with a simple moving average of -7.22% for the last 200 days.
Is It Worth Investing in Dyne Therapeutics Inc (NASDAQ: DYN) Right Now?
The stock has a 36-month beta value of 1.09. Opinions on the stock are mixed, with 6 analysts rating it as a “buy,” 3 as “overweight,” 4 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for DYN is 77.01M, and at present, short sellers hold a 12.91% of that float. On November 21, 2024, the average trading volume of DYN was 1.27M shares.
DYN) stock’s latest price update
Dyne Therapeutics Inc (NASDAQ: DYN)’s stock price has plunge by 1.04relation to previous closing price of 29.68. Nevertheless, the company has seen a -12.13% plunge in its stock price over the last five trading sessions. seekingalpha.com reported 2024-11-11 that Dyne Therapeutics, Inc. develops treatments for muscle diseases using its FORCE platform, with promising candidates DYNE-101 and DYNE-251 targeting DM1 and DMD, respectively. DYNE-251 shows significant improvement over Sarepta’s Eteplirsen in Phase 1/2 trials, potentially accelerating approval and boosting DYN’s stock. Key risks include executive reshuffling and potential hidden issues with IP, but current data and market potential make DYN attractive for speculative investors.
Analysts’ Opinion of DYN
Many brokerage firms have already submitted their reports for DYN stocks, with JP Morgan repeating the rating for DYN by listing it as a “Neutral.” The predicted price for DYN in the upcoming period, according to JP Morgan is $35 based on the research report published on October 24, 2024 of the current year 2024.
Chardan Capital Markets, on the other hand, stated in their research note that they expect to see DYN reach a price target of $42, previously predicting the price at $31. The rating they have provided for DYN stocks is “Buy” according to the report published on May 21st, 2024.
Morgan Stanley gave a rating of “Overweight” to DYN, setting the target price at $40 in the report published on April 30th of the current year.
DYN Trading at -7.19% from the 50-Day Moving Average
After a stumble in the market that brought DYN to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -36.80% of loss for the given period.
Volatility was left at 6.65%, however, over the last 30 days, the volatility rate increased by 8.63%, as shares sank -7.32% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -8.01% lower at present.
During the last 5 trading sessions, DYN fell by -12.13%, which changed the moving average for the period of 200-days by +36.69% in comparison to the 20-day moving average, which settled at $29.69. In addition, Dyne Therapeutics Inc saw 125.49% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at DYN starting from Incerti Carlo, who sale 16,500 shares at the price of $28.73 back on Nov 18 ’24. After this action, Incerti Carlo now owns 0 shares of Dyne Therapeutics Inc, valued at $474,045 using the latest closing price.
Rhodes Jason P, the Director of Dyne Therapeutics Inc, sale 782 shares at $33.10 during a trade that took place back on Nov 14 ’24, which means that Rhodes Jason P is holding 15,962 shares at $25,884 based on the most recent closing price.
Stock Fundamentals for DYN
Current profitability levels for the company are sitting at:
- -83.02 for the present operating margin
- 0.64 for the gross margin
The net margin for Dyne Therapeutics Inc stands at -77.75. The total capital return value is set at -0.43. Equity return is now at value -68.69, with -60.47 for asset returns.
Currently, EBITDA for the company is -233.48 million with net debt to EBITDA at 1.62. When we switch over and look at the enterprise to sales, we see a ratio of 671.77. The liquidity ratio also appears to be rather interesting for investors as it stands at 17.02.
Conclusion
To sum up, Dyne Therapeutics Inc (DYN) has seen a mixed performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
